Successful Utilization of High-Flux Hemodialysis for Treatment of Vancomycin Toxicity in a Child by Stidham, Timothy et al.
Hindawi Publishing Corporation
Case Reports in Pediatrics
Volume 2011, Article ID 678724, 4 pages
doi:10.1155/2011/678724
Case Report
SuccessfulUtilization of High-Flux Hemodialysisfor
Treatmentof VancomycinToxicity in aChild
Timothy Stidham,1 Pamela D. Reiter,2 DouglasM. Ford,3 GaryM. Lum,3 and Joseph Albietz4
1Pediatric Intensive Care Unit, Section of Critical Care Medicine, Children’s Hospital Colorado and University of Colorado at Denver,
13123 East 17th Avenue, Mail Stop 8414, Aurora, CO 80045, USA
2Pediatric Intensive Care Unit, Department of Pharmacy, Center for Pediatric Medicine, Children’s Hospital Colorado and
University of Colorado Denver School of Pharmacy, 13123 East 17th Avenue, Campus Box 375, Aurora, CO 80045, USA
3Department of Nephrology, University of Colorado at Denver and Children’s Hospital Colorado, 13123 East 16th Avenue,
Campus Box B328, Aurora, CO 80045, USA
4Pediatric Intensive Care Unit, Section of Critical Care Medicine, University of Colorado at Denver and Children’s Hospital Colorado,
13123 East 17th Avenue, Campus Box B530, Aurora, CO 80045, USA
Correspondence should be addressed to Timothy Stidham, timothy.stidham@childrenscolorado.org
Received 2 November 2011; Accepted 28 December 2011
Academic Editors: N. Arslan and D. Fischer
Copyright © 2011 Timothy Stidham et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Vancomycin is routinely used for empiric antibiotic therapy in children. Higher-serum-concentration targets for serious infections
are now being recommended. This recommendation may result in aggressive dosing with increased potential for toxicity. We
report a case of a pediatric patient who developed vancomycin toxicity and associated oliguric renal failure who was treated
eﬀectively with high-ﬂux hemodialysis for vancomycin toxicity, clearing serum concentrations of vancomycin by over 75% in only
6 hours (213.2mcg/mL to 51.8mcg/mL) with subsequent return to baseline renal function and without adverse sequelae. While
not historically considered a viable option for drug removal in cases of toxicity, new high-ﬂux hemodialysis techniques can remove
signiﬁcant percentages of vancomycin in short periods of time.
1.Background
Vancomycin is a narrow-spectrum tricyclic glycopeptide an-
tibiotic with bactericidal activity against a variety of gram-
positive organisms including Staphylococcus epidermidis,
Staphylococcus aureus (both methicillin-sensitive (MSSA)
and- resistant strains (MRSA)), streptococci, enterococci,
and diphtheroids. It is often selected as part of empiric
therapyforpresumedseriousbacterialinfectionsinchildren.
Since bacterial killing by vancomycin is considered time
dependent, it is important to maintain vancomycin serum
concentrations above the minimum inhibitory concentra-
tion (MIC) of the organism for at least 40–50% of a dosing
interval [1]. Historically, MIC values for susceptible organ-
isms were less than 2mcg/mL, making a target serum trough
concentration of 5–10mcg/mL acceptable for therapeutic
success. Today, however, the MIC values are higher, in part
from the increase in resistant microorganisms. Vancomycin
dosing recommendations, in turn, have been increased in
order to achieve higher serum concentrations. Recent adult
guidelines for pneumonia (hospital acquired and ventilator
associated)andmeningitisnowrecommendachievingavan-
comycin serum trough concentration of 15–20mcg/mL [2–
4]. Although pediatric recommendations are not included in
these guidelines, higher concentrations of vancomycin are
now being targeted in children on a routine basis. These
higher serum concentrations may increase the likelihood of
vancomycin-associated nephrotoxicity. Historically, dialysis
has not been a highly eﬀective therapy in the treatment
of vancomycin toxicity. We report a case of vancomycin-
associated nephrotoxicity, successfully treated with high-
eﬃciency dialysis, in a child requiring high-dose therapy
to achieve serum trough concentrations within the newly
recommended target of 15–20mcg/mL.2 Case Reports in Pediatrics
2. Case Presentation
A seven-year-old female with congenital hydrocephalus
requiring placement of a ventriculoperitoneal shunt (VPS)
at 18 months of age with recent shunt revision was admitted
to our tertiary care children’s hospital with cellulitis around
the abdominal incision, malaise, poor enteral intake, and
headache. An operative procedure was performed to exter-
nalize her shunt. Wound cultures from the incision grew
MRSA and Streptococcal anginosus (milleri), and cultures
fromhershunttipgrewEnterobactercloacae.Shewasinitially
placed on ceftriaxone 50mg/kg intravenous (IV) every 12
hours and vancomycin 15mg/kgIV every 8 hours with a goal
trough vancomycin concentration of 15mcg/mL and goal
peak of 35–40mcg/mL. Blood was collected and revealed
a trough of 3.7mcg/mL and a peak of 16.9mcg/mL—
both below target. The vancomycin regimen was increased
to 25mg/kgIV every 6 hours with a resulting trough of
11.2mcg/mL and peak of 25.2mcg/mL (end of infusion
peak = 34mcg/mL). While the peak concentration was
adequateforthiscentralnervoussysteminfection,thetrough
concentration was below target. Vancomycin was further
increased to 29mg/kgIV every 6 hours. Subsequent serum
concentrations with the third dose revealed a therapeutic
trough of 15mcg/mL and a peak of 34.6mcg/mL (end of
infusion peak = 50mcg/mL). Due to the requirement of this
aggressive dosing regimen, surveillance serum creatinine was
requested every 2-3 days. Four days later, the child’s urine
output had fallen from 2.4mL/kg/hr to below 1mL/kg/hour,
and she showed clinical signs of ﬂuid overload with peri-
orbital edema and ascites. Laboratory analysis revealed a
serum creatinine of 3.47mg/dL (baseline = 0.28mg/dL on
admission). Serum potassium was within normal limits
(3.8mmol/L). Serum bicarbonate was low (15mmol/L).
Vancomycin was held and a 9-hour postdose concentration
was 213mcg/mL. Upon review of her medication proﬁle,
she had been exposed to multiple doses of ketorolac and
ibuprofen for postoperative pain management.
The patient’s acute oliguric renal insuﬃciency and exces-
sive vancomycin concentration prompted a renal consult.
A renal ultrasound was obtained that showed bilateral
increased renal echogenicity consistent with medical renal
disease and demonstrated no anatomic renal anomaly to
explain her acute renal insuﬃciency. Her vital signs upon
admission to the pediatric intensive unit were notable only
for slight tachycardia with heart rate 132, blood pressure
106/70, respiratory rate 20, and 100% saturated on room air.
Access for hemodialysis was obtained using a Dual Lumen 9
French, 12cm central venous catheter placed into the right
femoral vein. Hemodialysis was performed using a F40S hi-
ﬂuxpolysulfonedialyzer,140Na,4Kand35HCO3 bath,and
a blood ﬂow rate of up to 180mL/min was achieved. During
dialysisshealsoreceivedfurosemidetopromoteurineoutput
and decrease intrarenal vancomycin accumulation. Serial
vancomycin concentrations were collected during dialysis
(Figure 1), and dialysis was stopped after 6 hours when a
concentration of less than 50mcg/mL was achieved. The
patient tolerated dialysis well with periodic albumin and
saline support. Her postdialysis vital signs were stable (blood
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Figure 1: Concentration-time curve of vancomycin in a 7-year-old
child. Initial concentration was collected nine hours after a dose.
Shaded area indicates time of active high-ﬂux hemodialysis therapy.
Total dialysis time = 6h o u r s .
pressure = 91/40mmHg; heart rate = 141 beats per minute),
426mL of ﬂuid was removed, and total of 150mL ﬂuids
(albumin and saline) infused for net positive ﬂuid balance of
276mL.Serumcreatininevaluesalsodeclinedduringdialysis
from a peak of 3.59mg/dL to a nadir of 1.09mg/dL.
Aftercompletionofthedialysisprocedure,shewastrans-
ferred back to the medical ﬂoor in stable condition. Serum
vancomycin and creatinine concentrations were followed
every 12 hours for 2 days and then daily until within normal
limits for age. There was a noticeable redistribution eﬀect of
vancomycin following cessation of dialysis (Figure 1)w i t h
a resulting rise in vancomycin concentration to a second
peak of 73.9mcg/mL 22 hours after stopping dialysis. Serum
vancomycin levels steadily declined over the next 3 days.
Likewise, serum creatinine values initially increased after
completion of dialysis but then declined over the following
days to 0.49mg/dL prior to discharge. Antibiotic therapy was
changed to linezolid and levoﬂoxacin. 13 days after admis-
sion to the PICU, her external ventricular drain was removed
and replaced with a VPS. Because of the potential for
ototoxicity with high vancomycin concentrations, a hearing
evaluationwasperformed.Theauditorybrainstemresponses
demonstrated normal bilateral peripheral hearing sensitivity.
S h ew a su l t i m a t e l yd i s c h a r g e dh o m eo n c er e c u p e r a t e df r o m
her surgery and required no additional renal support.
3. Discussion
Vancomycin is eliminated by the kidneys via glomerular
ﬁltration [5]. When used alone, vancomycin is considered
minimally nephrotoxic—especially when targeting serum
trough concentrations of 5–10mcg/mL. The risk of nephro-
toxicity, however, increases with elevated serum trough
concentrations, prolonged duration of drug exposure,
concomitant use of other nephrotoxic medications (e.g.,
aminoglycosides, radiocontrast dye, furosemide, ampho-
tericin B and nonsteroidal anti-inﬂammatory agents), and
extracellular ﬂuid contraction [6, 7]. A recent evaluation
of vancomycin-associated nephrotoxicity identiﬁed nine
studies that reported elevated serum trough concentrations
(≥15mcg/mL) as a signiﬁcant predictor of nephrotoxicity
[8]. The inﬂuence of vancomycin dose and serum concen-
tration on the risk of developing nephrotoxicity in childrenCase Reports in Pediatrics 3
was studied among 167 children (age: 1 week–19 years) [9].
These investigators reported an overall nephrotoxicity rate
of 14%—which was signiﬁcantly higher in children who
attained a serum trough concentration above 15mcg/mL,
compared to those who achieved a trough concentration
below 15mcg/mL (28% versus 7.3%, P = 0.0001). It is
important to note that most reports describing vancomycin-
associated nephrotoxicity have been unable to ﬁrmly estab-
lish causation due to the inability to document the tem-
poral relationship of the onset of renal insuﬃciency and
vancomycin serum levels due to the inability to completely
rule out that renal function declined before the rise in serum
vancomycin concentration. In our case, it seems more likely
that vancomycin nephrotoxicity preceded renal dysfunction
because our patient had ample evidence of highly eﬃcient
vancomycin clearance early in her course and, other than
medication administration, sustained no other discernable
renal insult. Though the initiating factor is uncertain, once
acute renal insuﬃciency occurs, a positive feedback loop
is established, further compromising renal function. In our
case, the nephrotoxicity was likely compounded by exposure
to multiple doses of nonsteroidal anti-inﬂammatory agents
contemporaneous to vancomycin. Though most cases of
vancomycin-associated nephrotoxicity resolve upon discon-
tinuation of the medication, the markedly high serum
vancomycin levels, compounded by impaired clearance due
tooliguria,furtherincreasedtheriskofpersistentpermanent
renal injury and ototoxicity and warranted augmented
clearance through high-ﬂux hemodialysis.
Prior to the introduction of high-ﬂux hemodialysis
membranes for renal replacement therapies, a variety of
less eﬃcient modalities for the treatment of vancomycin
toxicity have been attempted. In patients with markedly
high plasma vancomycin concentrations but preserved renal
function, vancomycin elimination can be enhanced by
aggressive diuresis alone [10]. When more aggressive drug
removal has been indicated, especially in the presence of
renaldysfunction,conventionalmembranedialysisandchar-
coal hemoperfusion have been attempted but with limited
success. Standard membrane dialysis is largely ineﬀective
and much slower in clearing higher mass molecules such
as vancomycin (molecular weight approximately 1448 Dal-
tons). Alternative methods to remove vancomycin from the
intravascular space have included charcoal hemoperfusion
(CH), gastric dialysis using multidose activated charcoal and
exchange transfusion, with CH apparently the more eﬃcient
of the two [11]. While CH can remove approximately 40%
of vancomycin from the intravascular compartment, this
technique is accompanied by many adverse eﬀects including
hypocalcemia, hypothermia, hemodynamic compromise,
and thrombocytopenia [12]. Attempts to ameliorate these
adverse eﬀects of CH with the use of simultaneous HD have
had minimal success. Additionally, the shelf life of the CH
membrane is quite short, resulting in increased cost. As a
result, CH has largely been abandoned as a viable therapy
for vancomycin toxicity.
High-ﬂux hemodialysis is deﬁned by increased clearance
of middle-weight molecules (deﬁned by beta-2 microglob-
ulin clearance over 20mL/min). As compared to standard
hemodialysis, the membranes typically have a higher ultra-
ﬁltration coeﬃcient and are composed of either synthetic or
cellulose membranes. Disadvantages to the use of high-ﬂux
hemodialysis include the need for an automated ultraﬁltra-
tion control system with large extracorporeal circuit, higher
cost of the machines compared to conventional dialysis
machines, and like other forms of hemodialysis reliable
central venous access is a necessity [13]. Despite these draw-
backs, the larger pore size of high-ﬂux membranes allows for
enhancedeliminationoflargermoleculesandprotein-bound
molecules, previously not amenable to hemodialysis.
Our report highlights the safety and eﬀectiveness of
dialysis with an F40S hi ﬂux polysulfone dialyzer to rapidly
clear vancomycin from a pediatric patient in acute oliguric
renal insuﬃciency. Previous reports of vancomycin intox-
ication managed with high-eﬃciency dialysis membranes
have reported vancomycin removal rates between 60 and 79
percent [11, 14]. Removal of vancomycin in our pediatric
case was approximately 75 percent.
4. Conclusion
The current recommendations to target higher serum levels
of vancomycin are likely to result in an increased incidence
of adverse eﬀects, including unintended drug accumulation
and nephrotoxicity. Our report emphasizes the importance
of vigilant monitoring of vancomycin levels and renal
function with high-dose vancomycin and demonstrates the
safety, eﬃcacy, and superiority of high-ﬂux hemodialysis
as a method to remove extremely elevated vancomycin
concentrations from the intravascular space. We were able
to remove 75.68% of vancomycin within a 6-hour period
(213.2mcg/mL to 51.8mcg/mL) without any adverse eﬀects,
with full recovery of renal function, and preservation of
hearing. High-ﬂux hemodialysis should be considered as
a viable therapy in children with vancomycin toxicity and
concurrent renal insuﬃciency.
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